Novartis' Indian patent fight continues in court; Cipla eyes supply deal with Planned Parenthood;

 @FiercePharma: WSJ's story on the Chinese drug-price cuts: Report | Follow @FiercePharma

> Final hearings have begun before India's Supreme Court in Novartis' ($NVS) fight for a patent on its cancer drug Glivec. Report

> India's Cipla, targeting expansion of its contraceptive franchise, is in talks with International Planned Parenthood about supplying its birth control pills to developing countries. Report

> A Finnish drugmaker supplied medicines to the country's ski team, in violation of anti-doping rules, but the arrangement ended in 1998 and the company won't be prosecuted. Report

> Jazz Pharmaceuticals' stock leapt 14% on a judge's ruling in favor of the patent on its narcolepsy drug Xyrem. Report

> Sunovion Pharmaceuticals launched its antipsychotic drug Latuda in Canada. Report

> Pfizer ($PFE) published a guide for safe disposal of medicines aimed at healthcare providers. Report

Medical Device News

 @FierceMedDev: BioFire Diagnostics pulls in $25M in new funding for accelerated product development. Release | Follow @FierceMedDev

 @MarkHFierce: The iPhone 5 could accelerate the migration of medical devices to Bluetooth, eWeek reports. More | Follow @MarkHFierce

 @DamianFierce: Medtronic is looking to pair its pump technology with the next generation of Alzheimer's drugs. Report | Follow @DamianFierce

> J&J plans innovation centers, looking for buys and team-ups. Story

> Navidea launches PhII for Alzheimer's imaging. News

Biotech News

 @FierceBiotech: Bedside blood infection test being developed for sepsis. Item | Follow @FierceBiotech

 @JohnCFierce: Interesting: J&J setting up 4 deal teams around the globe - Boston. California. China and London. Via Reuters: Report | Follow @JohnCFierce

 @RyanMFierce: Fierce 15 arrives tomorrow. Here are some details on what to expect: More | Follow @RyanMFierce

> Medtronic dangles Alzheimer's delivery tech to frustrated pharmas. Story

> Software mogul commits $104M to CureVac's cancer vax work. More

Pharma Manufacturing News

> Gelatin prices look to rise steeply. Story

> Boehringer Ingelheim closing 1 of 3 U.S. API plants. More

> India says it will meet EU's API quality deadline. Report

Biotech Research News

> Mayo Clinic spies enzyme that destroys brain-clogging Alzheimer's protein. More

> Drug combo packs punch fighting rare form of melanoma in mice. Story

> UMass sensor array 'smelled' metastatic cancer cells in preclinical study. Article

And Finally ... FDA slapped Lancôme for claims made about its anti-aging creams. Report

Suggested Articles

J&J's talc woes deepened Friday after the FDA turned up "sub-trace" levels of asbestos one bottle of the company's baby powder,…

Another major drugmaker is recalling in the U.K. 10 batches of its Zantac generics because they contain a possible carcinogen.

With diagnosis rates on the rise, Pfizer's Vyndaqel franchise could collect $157 million in 2019 U.S. sales, well above consensus, SVB Leerink says.